doi: 10.1161/hc5001.101749
(Circulation. 2001;104:3023.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure
From the Department of Internal Medicine IV, Division of Cardiology, Johann W. Goethe–University Frankfurt, Germany.
Correspondence to Andreas M. Zeiher, MD, Department of Internal Medicine IV, Division of Cardiology, Johann W. Goethe–University, Theodor Stern Kai 7, D-60590 Frankfurt, Germany. E-mail zeiher{at}em.uni-frankfurt.de
Background— Anti–tumor necrosis factor (TNF)-
therapy with etanercept, a recombinant TNF receptor that binds to and functionally inactivates TNF-, was shown to improve the functional status of patients with congestive heart failure (CHF). Because administration of TNF- has been shown experimentally to depress endothelium-dependent relaxation, we hypothesized that TNF- antagonism with etanercept might improve the depressed systemic endothelial vasodilator function, which importantly contributes to increased peripheral vascular resistance in patients with advanced CHF.
Methods and Results— Endothelium-dependent (acetylcholine, ACH; 10 to 50 µg/min) and endothelium-independent (sodium nitroprusside, SNP; 2 to 8 µg/min) forearm blood flow (FBF) responses were measured by venous occlusion plethysmography in 13 patients with documented CHF (New York Heart Association class III) before, 6 hours after, and 7 days after subcutaneous injection of a single dose of 25 mg etanercept. Maximum ACH-induced FBF increased significantly from 6.9±1.0 to 13.0±1.6 mL/min per 100 mL of forearm tissue (P<0.05) 6 hours after administration of etanercept and returned to 7.0±1.1 mL/min per 100 mL of forearm tissue after 7 days (P=NS), whereas SNP-induced FBF responses were not significantly affected. In contrast, FBF responses were not altered in control CHF patients, who did not receive etanercept (n=5). Etanercept-induced increases in ACH-mediated FBF were closely correlated with baseline TNF- serum levels (r=0.66; P<0.02).
Conclusions— The administration of etanercept profoundly improves systemic endothelial vasodilator capacity in patients with advanced heart failure, suggesting an important role of inflammatory mediators for impaired endothelial vasoreactivity in CHF. Improvement of systemic endothelial function might importantly contribute to the beneficial effects of etanercept on the functional status of patients with CHF.
Key Words: inflammation • nitric oxide • endothelium • heart failure
This article has been cited by other articles:
 |
|
 |
|
  B. L. Goodwin, L. C. Pendleton, M. M. Levy, L. P. Solomonson, and D. C. Eichler Tumor necrosis factor-{alpha} reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1115 - H1121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Doehner, A. C. Bunck, M. Rauchhaus, S. von Haehling, F. M. Brunkhorst, M. Cicoira, C. Tschope, P. Ponikowski, R. A. Claus, and S. D. Anker Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow Eur. Heart J., April 1, 2007; 28(7): 821 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Csiszar, N. Labinskyy, K. Smith, A. Rivera, Z. Orosz, and Z. Ungvari Vasculoprotective Effects of Anti-Tumor Necrosis Factor-{alpha} Treatment in Aging Am. J. Pathol., January 1, 2007; 170(1): 388 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kota, C. V. Ramana, F. A. Tenorio, R. I. Enelow, and J. C. Rutledge Differential Effects of Lipoprotein Lipase on Tumor Necrosis Factor-{alpha} and Interferon-{gamma}-mediated Gene Expression in Human Endothelial Cells J. Biol. Chem., September 2, 2005; 280(35): 31076 - 31084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Vila and M. Salaices Cytokines and vascular reactivity in resistance arteries Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1016 - H1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fichtlscherer, S. Breuer, and A. M. Zeiher Prognostic Value of Systemic Endothelial Dysfunction in Patients With Acute Coronary Syndromes: Further Evidence for the Existence of the "Vulnerable" Patient Circulation, October 5, 2004; 110(14): 1926 - 1932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gerli, G. Schillaci, A. Giordano, E. B. Bocci, O. Bistoni, G. Vaudo, S. Marchesi, M. Pirro, F. Ragni, Y. Shoenfeld, et al. CD4+CD28- T Lymphocytes Contribute to Early Atherosclerotic Damage in Rheumatoid Arthritis Patients Circulation, June 8, 2004; 109(22): 2744 - 2748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Olsen and C. M. Stein New Drugs for Rheumatoid Arthritis N. Engl. J. Med., May 20, 2004; 350(21): 2167 - 2179. [Full Text] [PDF]
|
|
|
|
 |
|
 I. A. Arenas, Y. Xu, P. Lopez-Jaramillo, and S. T. Davidge Angiotensin II-induced MMP-2 release from endothelial cells is mediated by TNF-{alpha} Am J Physiol Cell Physiol, April 1, 2004; 286(4): C779 - C784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. I. Anderson, D. Rahmutula, and D. G. Gardner Tumor Necrosis Factor-{alpha} Inhibits Endothelial Nitric-oxide Synthase Gene Promoter Activity in Bovine Aortic Endothelial Cells J. Biol. Chem., January 9, 2004; 279(2): 963 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Morita, N. Ukyo, M. Furuya, T. Uchiyama, and T. Hori Atrial Natriuretic Peptide Polarizes Human Dendritic Cells Toward a Th2-Promoting Phenotype Through Its Receptor Guanylyl Cyclase-Coupled Receptor A J. Immunol., June 15, 2003; 170(12): 5869 - 5875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chia, M. Qadan, R. Newton, C. A. Ludlam, K. A.A. Fox, and D. E. Newby Intra-Arterial Tumor Necrosis Factor-{alpha} Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 695 - 701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Faraci Hyperhomocysteinemia: A Million Ways to Lose Control Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 371 - 373. [Full Text] [PDF]
|
|
|
|
 |
|
 P A Henriksen and D E Newby Therapeutic inhibition of tumour necrosis factor {alpha} in patients with heart failure: cooling an inflamed heart Heart, January 1, 2003; 89(1): 14 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Schachinger and A. M. Zeiher Atherogenesis--recent insights into basic mechanisms and their clinical impact Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2055 - 2064. [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Mann Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future Circ. Res., November 29, 2002; 91(11): 988 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hurlimann, A. Forster, G. Noll, F. Enseleit, R. Chenevard, O. Distler, M. Bechir, L. E. Spieker, M. Neidhart, B. A. Michel, et al. Anti-Tumor Necrosis Factor-{alpha} Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis Circulation, October 22, 2002; 106(17): 2184 - 2187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Vallbracht, P. L. Schwimmbeck, B. Seeberg, U. Kuhl, and H.-P. Schultheiss Endothelial dysfunction of peripheral arteries in patients with immunohistologically confirmed myocardial inflammation correlates with endothelial expression of human leukocyte antigens and adhesion molecules in myocardial biopsies J. Am. Coll. Cardiol., August 7, 2002; 40(3): 515 - 520. [Abstract] [Full Text] [PDF]
|
|